SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences - Quaterly Results

05 Aug 2025 Evaluate
The sales for the June 2025 quarter moved up 26.70% to Rs. 5786.40 millions as compared to Rs. 4566.90 millions during the corresponding quarter last year.Net Profit witnessed a 486.80% growth almost the double from Rs. 170.40 millions to Rs. 999.90  millions  of same quarter last year.The company reported a good operating profit of 2390.00 millions compared to 1285.40 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 5786.40 4566.90 26.70 5786.40 4566.90 26.70 16977.50 14867.10 14.20
Other Income 226.80 51.60 339.53 226.80 51.60 339.53 355.10 348.30 1.95
PBIDT 2390.00 1285.40 85.93 2390.00 1285.40 85.93 5220.60 4886.50 6.84
Interest 451.40 561.70 -19.64 451.40 561.70 -19.64 2202.40 574.20 283.56
PBDT 1938.60 723.70 167.87 1938.60 723.70 167.87 3018.20 4312.30 -30.01
Depreciation 376.00 455.50 -17.45 376.00 455.50 -17.45 1817.70 1023.90 77.53
PBT 1562.60 268.20 482.62 1562.60 268.20 482.62 1200.50 3288.40 -63.49
TAX 562.70 97.80 475.36 562.70 97.80 475.36 426.60 291.20 46.50
Deferred Tax 291.00 50.90 471.71 291.00 50.90 471.71 206.80 -285.20 -172.51
PAT 999.90 170.40 486.80 999.90 170.40 486.80 773.90 2997.20 -74.18
Equity 136.20 136.10 0.07 136.20 136.10 0.07 136.20 136.00 0.15
PBIDTM(%) 41.30 28.15 46.75 41.30 28.15 46.75 30.75 32.87 -6.44

Eris Lifesciences Share Price

1392.80 41.50 (3.07%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×